Elham Aminifar; Hassan Mehrad-Majd; Yalda Ravanshad; Amirhossein Sahebkar
Abstract
Introduction: Small nucleolar RNA host genes (SNHGs) are a class of long non-coding RNAs that have been increasingly associated with various cancers and are emerging as key players in cancer progression.This systematic review aimed to analyze the expression patterns and potential roles of SNHG5, SNHG17, ...
Read More
Introduction: Small nucleolar RNA host genes (SNHGs) are a class of long non-coding RNAs that have been increasingly associated with various cancers and are emerging as key players in cancer progression.This systematic review aimed to analyze the expression patterns and potential roles of SNHG5, SNHG17, and SNHG26 in various solid tumors.Methods: A comprehensive literature search was conducted across databases including PubMed, Cochrane, and Google Scholar, to identify relevant studies. Initially retrieved papers were screened based on titles and abstracts for relevance, with exclusion criteria applied to eliminate duplicate publications, case reports, conference abstracts, and irrelevant studies.Results: A total of 21 papers met the criteria for this systematic review, focusing on SNHG5 (5 articles), SNHG17 (7 articles), and SNHG26 (9 articles). These studies consistently highlighted the upregulation of SNHG5, SNHG17, and SNHG26 in various cancer types, emphasizing their potential as prognostic and therapeutic targets in solid tumors.Conclusion: The findings suggest a consistent overexpression of SNHG5, SNHG17, and SNHG26 in cancerous tissues, supporting their potential as prognostic markers in solid tumors. Further investigations should consider the regulatory mechanisms of SNHGs and explore their therapeutic implications in cancer management. This review highlights the importance of understanding the roles of SNHGs in cancer progression and calls for continued research efforts.
Sahar Ravanshad; Marieh Alizadeh; Aida Bakhshi; Sepideh Hejazi; Mina AkbariRad; Hassan Mehrad-Majd
Abstract
Introduction: The COVID-19 pandemic has underscored the necessity of investigating the relationship between radiological and laboratory findings with disease outcome in COVID-19 patients. This study aimed to explore the association between CT-scan finding and laboratory results with disease outcome, ...
Read More
Introduction: The COVID-19 pandemic has underscored the necessity of investigating the relationship between radiological and laboratory findings with disease outcome in COVID-19 patients. This study aimed to explore the association between CT-scan finding and laboratory results with disease outcome, including recovery without complications, ICU admission, or mortality.Methods: This retrospective cross-sectional study analyzed medical records and laboratory data from COVID-19 patients at our institution from September 2020 onwards. All demographic, laboratory findings, as well as CT-scan data such as ground-glass opacity, consolidation, pleural effusion, cardiomegaly, mediastinal lymphadenopathy, and pulmonary involvement score at admission were collected. Patients were categorized based on outcome status and compared for all study variables. Results: Significance differences were observed for CT-score values between deceased patients and those who recovered (P<0.001), indicating a more severe lung changes in patients who died due to COVID-19. Additionally ICU-admitted patients had higher likelihood of underlying comorbidities and elevated CT-score levels. Laboratory markers such as ESR, Ferritin, LDH, Neutrophil count, and RDW were significantly higher in patients requiring ICU admission (P<0.05). Deceased patients were more likely to have underlying diseases, ground glass opacity, cardiomegaly, and higher CT-scores. Laboratory markers such as ESR, CRP, Ferritin, LDH, and others were also significantly higher in expired patients.Conclusion: There was a strong association between laboratory and CT-scan findings with disease outcomes in COVID-19 patients. The combination of laboratory markers and CT-scan findings can serve as robust predictors of disease outcomes. Further studies are needed to validate these findings in larger cohorts.
Sahar Ravanshad; Zahra Fahimian; Parsa Shoghi; Ali Moradi; Valareza Alizadeh; Negar Javdan; Hassan Mehrad-Majd
Abstract
Introduction: Studying the survival factors of leukemia patients can lead to a reduction in healthcare costs. This study aimed to evaluate the survival rate and potential predictive factors in leukemia patients in northeast Iran.Methods: Baseline demographic and clinical data of patients referred to ...
Read More
Introduction: Studying the survival factors of leukemia patients can lead to a reduction in healthcare costs. This study aimed to evaluate the survival rate and potential predictive factors in leukemia patients in northeast Iran.Methods: Baseline demographic and clinical data of patients referred to Ghaem Hospital between 2014 and 2019 were extracted from their medical records. The survival rates were determined by gathering information from phone calls or archived files.Results: This cohort study consisted of 302 patients with a mean age of 41.09±19.09 years. Among them, 127 (43.3%) had acute lymphoid leukemia, while 166 (56.7%) had myeloid leukemia. The mean overall survival time for all patients was 50.81 months. However, the mean overall survival time for patients with lymphoid leukemia (61.7 months) was significantly higher (P<0.001) than that for patients with myeloid leukemia (41.1 months). Moreover, lymphoid patients had significantly higher one-month and one-year survival rates (93% and 72.8%) than the myeloid group (81% and 53.7%) (P=0.002 and P=0.001). However, significant difference did not exist in the five-year survival rate between the lymphoid and myeloid groups (26.2% vs 18.2%, P=0.174). Cox regression analysis indicated that patient survival was correlated with the type of leukemia (1.45, 95%CI=1.10-8.92, P=0.011), age, hemoglobin levels, as well as WBC, RBC, neutrophil, and platelet count.Conclusion:Our findings indicated that patients with lymphoid leukemia exhibited a higher survival rate than those with myeloid leukemia. Survival outcomes were dependent on patient’s age, leukemia type, and levels of WBC, RBC, neutrophil, platelet, and hemoglobin levels.
kamila Hashemzadeh; Ali Esparham; Farnoosh Ebrahimzadeh; Konstantinos Triantafyllias; Zahra Mirfeizi; Maryam Sahebari; Mohammad Hassan J Joker; Mandana Khodashahi; Masoumeh Salari; Bita Abbasi; Delaram Omidvar; Mahtab Ghaemi; Hassan Mehrad-Majd
Abstract
Introduction: Health care systems all over the world face numerous challenges as a result of the rapid spread of the COVID-19 virus that has resulted in increased mortality rates. About 40% of ICU-admitted COVID-19 patients were not severely ill at the time of admission. Thus, by using appropriate ICU ...
Read More
Introduction: Health care systems all over the world face numerous challenges as a result of the rapid spread of the COVID-19 virus that has resulted in increased mortality rates. About 40% of ICU-admitted COVID-19 patients were not severely ill at the time of admission. Thus, by using appropriate ICU admission predictors, clinicians can identify potential critical patients early on. It can also result in suitable resource allocation and consideration for these patients. Therefore, the current study was done with the aim of identifying clinical characteristics and laboratory data that could predict ICU admission in cases with COVID-19.Methods: This two-center retrospective observational study was done in Imam Reza and Ghaem Hospitals, Mashhad, Iran. Overall, 334 COVID-19 patients who referred to these hospitals from February to May 2020 were enrolled in this study. The participants were separated into two groups according to ICU admission status. All demographic, clinical, and paraclinical information were extracted from the medical records of the patients. Results: The present study composed of 88 ICU and 246 non-ICU-admitted COVID-19 patients. No significant differences were found in age between the two groups of patients (P=0.154). Multivariate regression analysis revealed that higher levels of CRP (OR=1.01, 95%CI 1.001-1.010, P=0.016), WBC (OR=1.11, 95% CI 1.01-1.22, P=0.03), and HRCT scores (OR=1.08, 95%CI=1.01-1.16, P=0.037) were linked to higher odds of ICU admission.Conclusion: This study suggests that higher levels of CRP, WBC, and LDH, as well as the HRCT score at the time of admission, were potential independent predictors of ICU admission during inpatient treatment in COVID-19 patients.
Hassan Mehrad-Majd; Javad Akhtari; Yalda Ravanshad
Abstract
Metabolic syndrome and its various manifestations are considered to be a significant health epidemic in the developed and developing countries across the world. Metabolic syndrome is characterized by a series of metabolic abnormalities, such as central adiposity, insulin resistance, hypertension, glucose ...
Read More
Metabolic syndrome and its various manifestations are considered to be a significant health epidemic in the developed and developing countries across the world. Metabolic syndrome is characterized by a series of metabolic abnormalities, such as central adiposity, insulin resistance, hypertension, glucose intolerance, and dyslipidemia. Patients with metabolic syndrome are at a higher risk of major complications, including fatty liver, type II diabetes mellitus, and cardiovascular diseases. Nuclear receptors are the key regulators of gene transcription, as well as several metabolic pathways. Among these receptors, LXRα and β play a major role in the regulation of lipogenesis, cholesterol/glucose homoeostasis, and inflammatory pathways through the induction or repression of target genes. In addition to metabolic homeostasis and diseases, lipogenesis and hypertriglyceridemia are regarded as the most significant adverse effects of liver X receptor (LXR) activation. Given the importance of lipid and carbohydrate metabolism and inflammation in the development of metabolic disorders, the present study aimed to review the impact of LXR signaling on the risk of metabolic syndrome and its phenotypes, with an emphasis on their potential therapeutic applications in the treatment of metabolic syndrome. In general, growing evidence supports the notion that LXRs may represent the potential drug targets for the treatment of metabolic syndrome.